Evidence map›Paper›PMID 34369038›Full record

ArticleJournal of biochemical and molecular toxicology2021

Suppression of reactive oxygen species in endothelial cells by an antagonist of growth hormone-releasing hormone.

Mohammad S Akhter, Nektarios Barabutis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biochemical and molecular toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. GHRH and its analogues in central nervous system diseases.Reviews in endocrine & metabolic disorders · 2025
    Review
  3. Effects of GHRH and its analogues on the Vascular System.Reviews in endocrine & metabolic disorders · 2025
    Review
  4. Growth hormone - releasing hormone in the immune system.Reviews in endocrine & metabolic disorders · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Growth hormone-releasing hormone antagonists counteract hydrogen peroxide - induced paracellular hyperpermeability in endothelial cells.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mohammad S AkhterSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA.
Nektarios BarabutisSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA.ORCID http://orcid.org/0000-0001-8366-5099
University of Louisiana at Monroe · US

Funding

STABILITY' (symptomatic review during biologic therapy) Review in Inflammatory Bowel DiseaseP20GM103424 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI Konstantin G Kousoulas · 2012 to 2026
$57.4M
Louisiana Board of Regents LEQSF(2019-22)-RD-A-26National Institute of General Medical Sciences of the National Institutes of Health 5 P20 GM103424-15, 3 P20 GM103424-15S1NIGMS NIH HHS P20 GM103424
6 · The paper itself

Abstract

Growth hormone-releasing hormone (GHRH) is a hypothalamic hormone, which regulates the secretion of growth hormone (GH) from the anterior pituitary gland. The effects of GHRH extend beyond the GH-insulin-like growth factor I axis, and that neuropeptide has been involved in the potentiation of several malignancies and other inflammatory disorders. The development of GHRH antagonists (GHRHAnt) delivers an exciting possibility to counteract the pathogenesis of the GHRH-related effects in human pathophysiology, especially when considered that GHRHAnt support endothelial barrier integrity. Those GHRHAnt-mediated effects are exerted at least in part due to the suppression of major inflammatory pathways, and the modulation of major cytoskeletal components. In the present study, we measured the production of reactive oxygen species (ROS) in bovine pulmonary artery endothelial cells, human cerebral microvascular endothelial cells, and human lung microvascular endothelial cells exposed to GHRH or a commercially available GHRHAnt. Our findings reveal the antioxidative effects of GHRHAnt in all three cell lines, which express GHRH receptors. The redox status of NIH/3T3 cells, which do not produce GHRH receptors, was not significantly affected by GHRH or GHRHAnt. Hence, the application of GHRHAnt in pathologies related to increased ROS production should be further investigated.

Indexed as

AnimalsCattleCell Line, TransformedEndothelial CellsGrowth Hormone-Releasing HormoneHumansHydrogen PeroxideMiceNIH 3T3 CellsPulmonary ArteryReactive Oxygen SpeciesReceptors, NeuropeptideReceptors, Pituitary Hormone-Regulating HormoneSignal TransductionGHRH protein, humanGrowth Hormone-Releasing HormoneHydrogen PeroxideReactive Oxygen SpeciesReceptors, NeuropeptideReceptors, Pituitary Hormone-Regulating Hormonesomatotropin releasing hormone receptorblood-brain barrierendothelial barrier functiongrowth hormonereactive oxygen species

Identifiers

PMID34369038
PMCPMC8526391
OpenAlexW3188671361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.